
Affimed prices public offering to finance NK cell trials
German Affimed N.V. has priced its previously announced public offering of 22,500,000 common shares at a $4.00 per common share. A 30-day...

Bayer Leaps to invests €1.3bn externally
"We are on the threshold of a new era of innovation in the life sciences." commented Werner Baumann, Chairman of the Board at Bayer...

Curevac NV sues BioNtech for IP infringement
On Monday, CureVac filed a lawsuit in the German Regional Court in Düsseldorf against BioNTech SE and two of its subsidiaries, seeking compensation...

$50m for London CHARM Therapeutics for deep minded folding expertise
London based CHARM Therapeutics rushes into the 3D deep-learning space with a $50M Series A financing co-led by F-Prime Capital and OrbiMed, with...

Study shows advantages of cellular agriculture
Replacing animal-source foods (ASFs) with novel or future foods (NFFs) – such as cultured milk, insect meal or mycoprotein – or plant-based...

Abliva decides on a SEK200m financing to fund Phase 2/3 study
Swedish Abliva is focussing on mitochondrial medicine, developing therapeutics for primary mitochondrial diseases, orphan indications of high unmet...

Roche obtains special authorisation for bispecific antibody
Roches new developed immunotherapy is based on a bispecific antibody, which targets B-lymphocyte antigen CD20 and the CD3-T-cell receptor at the...